GIM-531

PreclinicalSmall molecule

GGeorgiamune Inc

GIM-531 is one of 2 small molecule programs targeting Melanoma Stage IV. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Melanoma Stage IVRecruiting

Melanoma Stage IVPreclinical

Recruiting

Competition

Competitive Landscape

1 competitor in Melanoma Stage IV

#DrugCompanyPhaseTrials

Anti-PD-1 Monoclonal Antibody

IiTeos Therapeutics

Preclinical

1 2

GIM-531

GGeorgiamune Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Melanoma Stage IV

NCT06425926

Clinical

Trials by Indication[1]

Melanoma Stage IV1 trial

A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination With Anti-PD-1 in Advanced Solid Tumors

Recruiting·GGeorgiamune Inc·Preclinical·NCT06425926·117 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GIM-531. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GIM-531 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GIM-531. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Georgiamune Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGeorgiamune Inc

GIM-531

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Melanoma Stage IV1 trial

References

Drug Info

Quick Facts

Related News